Emergent Biosolutions (EBS) closed at $6.06 on November 6, 2026, up 3.6% from the previous close, on volume of 945,594 shares (30-day average 1,060,935).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Diagonal Call Spread | 19-Mar : 17-Jun-278 : 6 C | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Emergent BioSolutions Secures $22.3 Million Anthrax Vaccine Contract Modification
TipRanks (Wed, 4-Nov 4:47 PM ET)
Business Wire (Wed, 4-Nov 4:05 PM ET)
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Business Wire (Mon, 2-Nov 4:05 PM ET)
Emergent BioSolutions Flags a Long-Run CFO Transition, Naming Frank Vargo Interim CFO Starting 2027
Market Chameleon (Fri, 16-Oct 4:32 AM ET)
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Business Wire (Fri, 16-Oct 7:50 AM ET)
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
Business Wire (Thu, 15-Oct 8:00 AM ET)
PRNewswire (Thu, 24-Sep 6:39 PM ET)
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
Globe Newswire (Tue, 15-Sep 7:45 AM ET)
Globe Newswire (Thu, 3-Sep 7:45 AM ET)
Globe Newswire (Tue, 1-Sep 7:55 AM ET)
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Emergent Biosolutions trades on the NYSE stock market under the symbol EBS.
As of November 6, 2026, EBS stock price climbed to $6.06 with 945,594 million shares trading.
EBS has a beta of 0.63, meaning it tends to be less sensitive to market movements. EBS has a correlation of 0.01 to the broad based SPY ETF.
EBS has a market cap of $313.91 million. This is considered a Small Cap stock.
Last quarter Emergent Biosolutions reported $110 million in Revenue and -$.36 earnings per share. This fell short of revenue expectation by $-13 million and exceeded earnings estimates by $.04.
In the last 3 years, EBS traded as high as $15.10 and as low as $1.42.
The top ETF exchange traded funds that EBS belongs to (by Net Assets): AVUV, VTI, XBI, IWM, DFSV.
EBS has underperformed the market in the last year with a return of -41.0%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in EBS shares. However, EBS has outperformed the market in the last 3 month and 2 week periods, returning +14.1% and -2.7%, while SPY returned -4.1% and -3.2%, respectively. This indicates EBS has been having a stronger performance recently.
EBS support price is $5.57 and resistance is $6.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EBS shares will trade within this expected range on the day.
